Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

20091,056 citationsJournal Articlebronze Open Access

Authors

Mark D. Pescovitz · Indiana University School of Medicine

Carla J. Greenbaum · Benaroya Research Institute

Heidi Krause‐Steinrauf · George Washington University

Dorothy J. Becker · University of Pittsburgh

Stephen E. Gitelman · University of California, San Francisco

Robin Goland · Columbia University

Peter A. Gottlieb

Abstract

A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)

Topics & Keywords

Diabetes and associated disorders Diabetes Management and Research Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 22, pp. 2143-2152

DOI: 10.1056/nejmoa0904452

Field-Weighted Citation Impact: 50.91